You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The new multinational consortium, backed by the EU and Canada, seeks to improve understanding of immune responses and uncover new therapeutic targets.
The new, multinational iReceptor Plus Consortium will develop a platform for sharing of AIRR-seq data to advance immunotherapy and precision medicine.
The National Institutes of Health Commercial Accelerator Program helps small healthcare and life science companies bring their products to market.
Using the publicly available ImmPort database, researchers standardized and analyzed immune-related data for more than 10,300 healthy individuals.
The company is marketing the panel, which runs on NanoString Technologies' nCounter System, to chemical and cosmetics firms as a replacement for animal models.
Data for hundreds of thousands of participants led to 20 new risk loci for allergic rhinitis, which were further examined by functional annotation and fine mapping.
The test is based on the company's GARD platform for measuring genetic biomarkers of immune reactions to predict chemical sensitivities.
The lab will launch a carrier screening test this year, and plans to bring infectious disease, allergy, cognitive health, and toxicology tests as well.
With RNA sequencing on blood samples taken before, during, and after peanut exposure, investigators searched for acute allergy-related genes and cell types.
The Los Angeles Times reports that experts say Moderna's investigational COVID-19 vaccine results seem to be a step in the right direction, but that more testing is needed.
The Washington Post reports a new coronavirus data reporting protocol goes around the Centers for Disease Control and Prevention.
The Trump Administration has reversed its policy that could have stripped international students of their visas, the New York Times says.
In Cell this week: proteomic and metabolomic analysis of blood from COVID-19 patients, change in phosphorylation with infection, and more.